November 6, 2024 10:34 AM EST
News Briefing

Macro­Gen­ics paus­es de­vel­op­ment of ADC; Cel­lec­tis de­pri­or­i­tizes CAR-T

ENDPOINTS

Plus, news about Tan­go Ther­a­peu­tics, En­do, Neu­ro­gene and Cen­tu­ry Ther­a­peu­tics:

Macro­Gen­ics stopped dos­ing pa­tients in ADC tri­al: Af­ter three pa­tient deaths in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times